Literature DB >> 20842486

Myotonia congenita and myotonic dystrophy: surveillance and management.

Allison Conravey1, Lenay Santana-Gould.   

Abstract

OPINION STATEMENT: Myotonia can be treated both pharmacologically and by lifestyle modifications. Cell membrane stabilizers are the medications most commonly used for symptomatic treatment of myotonia. Most patients do not require treatment for the myotonia itself, unless it is severe, but physicians must be aware of anesthesia risks in both myotonia congenita and myotonic dystrophy. A mainstay of management of myotonic dystrophy is the surveillance and treatment of its various systemic complications.

Entities:  

Year:  2010        PMID： 20842486     DOI： 10.1007/s11940-009-0055-z

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN： 1092-8480            Impact factor:   3.598


  47 in total

1.  Response to treatment with antihistamines in a family with myotonia congenita.

Authors:  E F Hughes; J Wilson
Journal:  Lancet       Date:  1991-01-05       Impact factor: 79.321

Review 2.  Diagnostics and therapy of muscle channelopathies--Guidelines of the Ulm Muscle Centre.

Authors:  F Lehmann-Horn; K Jurkat-Rott; R Rüdel
Journal:  Acta Myol       Date:  2008-12

3.  Improved therapy of myotonia with the lidocaine derivative tocainide.

Authors:  R Rüdel; R Dengler; K Ricker; A Haass; W Emser
Journal:  J Neurol       Date:  1980       Impact factor: 4.849

4.  Relationships among electrophysiological findings and clinical status, heart function, and extent of DNA mutation in myotonic dystrophy.

Authors:  A Lazarus; J Varin; Z Ounnoughene; H Radvanyi; C Junien; J Coste; P Laforet; B Eymard; H M Becane; S Weber; D Duboc
Journal:  Circulation       Date:  1999-03-02       Impact factor: 29.690

5.  A pilot controlled study of the use of imipramine to reduce myotonia.

Authors:  G G Gascon; R D Staton; B D Patterson; P J Konewko; H Wilson; K M Carlson; R A Brumback
Journal:  Am J Phys Med Rehabil       Date:  1989-10       Impact factor: 2.159

6.  Dehydroepiandrosterone for myotonic dystrophy type 1.

Authors:  I Pénisson-Besnier; M Devillers; R Porcher; D Orlikowski; V Doppler; C Desnuelle; X Ferrer; M-C A Bes; F Bouhour; C Tranchant; E Lagrange; A Vershueren; D Uzenot; P Cintas; G Solé; J-Y Hogrel; P Laforêt; C Vial; A L Vila; S Sacconi; J Pouget; B Eymard; S Chevret; D Annane
Journal:  Neurology       Date:  2008-08-05       Impact factor: 9.910

7.  In vitro effects of propofol and volatile agents on pharmacologically induced chloride channel myotonia.

Authors:  Oliver Bandschapp; Hans F Ginz; Charles L Soule; Thierry Girard; Albert Urwyler; Paul A Iaizzo
Journal:  Anesthesiology       Date:  2009-09       Impact factor: 7.892

8.  Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study.

Authors:  Maggie C Walter; Peter Reilich; Hanns Lochmüller; Ralph Kohnen; Beate Schlotter; Hubert Hautmann; Elmar Dunkl; Dieter Pongratz; Wolfgang Müller-Felber
Journal:  J Neurol       Date:  2002-12       Impact factor: 4.849

Review 9.  Drug treatment for myotonia.

Authors:  J Trip; G Drost; B G M van Engelen; C G Faber
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

10.  Does modafinil enhance activity of patients with myotonic dystrophy?: a double-blind placebo-controlled crossover study.

Authors:  A R Wintzen; G J Lammers; J G van Dijk
Journal:  J Neurol       Date:  2007-02-06       Impact factor: 4.849
View more
  4 in total

1.  Paroxysmal kinesigenic dyskinesia and myotonia congenita in the same family: coexistence of a PRRT2 mutation and two CLCN1 mutations.

Authors:  Hong-Fu Li; Wan-Jin Chen; Wang Ni; Zhi-Ying Wu
Journal:  Neurosci Bull       Date:  2014-09-05       Impact factor: 5.203

2.  Oral motor movements and swallowing in patients with myotonic dystrophy type 1.

Authors:  Beatriz Ercolin; Fernanda Chiarion Sassi; Laura Davison Mangilli; Lucia Iracema Zanotto Mendonça; Suelly Cecilia Olivan Limongi; Claudia Regina Furquim de Andrade
Journal:  Dysphagia       Date:  2013-03-05       Impact factor: 3.438

3.  The Effects of the KCNQ Openers Retigabine and Flupirtine on Myotonia in Mammalian Skeletal Muscle Induced by a Chloride Channel Blocker.

Authors:  Tzu-Rong Su; Wen-Shan Zei; Ching-Chyuan Su; George Hsiao; Min-Jon Lin
Journal:  Evid Based Complement Alternat Med       Date:  2012-03-25       Impact factor: 2.629

4.  Myotonia congenita and periodic hypokalemia paralysis in a consanguineous marriage pedigree: Coexistence of a novel CLCN1 mutation and an SCN4A mutation.

Authors:  Chenyu Zhao; DongFang Tang; Hui Huang; Haiyan Tang; Yuan Yang; Min Yang; Yingying Luo; Huai Tao; Jianguang Tang; Xi Zhou; Xiaoliu Shi
Journal:  PLoS One       Date:  2020-05-14       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.